Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis

Inclusion Criteria

• •Histologically proven initial diagnosis of adenocarcinoma of the prostate;
• •Biochemical relapse of PCa following radical local prostate treatment (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed adjuvant/salvage radiotherapy) +/- ADT according to the European Association of Urology (EAU) guidelines 2016 \[18\] or after any salvage therapy if biochemical progression is diagnosed in the context of castration sensitive PCa;
• •Nodal relapse in the pelvis, extra-regional nodal relapse (M1a), bone metastases (M1b) on Ch-PET/CT or WBMRI with a maximum of 3 lesions;
• •Serum testosterone level \>50 ng/dl at the time of randomization (castration sensitive PCa)
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
• •Age ≥18 years;
• •Written informed consent signed